TY - JOUR
T1 - The 2018 assisi think tank meeting on breast cancer
T2 - International expert panel white paper
AU - Arenas, Meritxell
AU - Selek, Ugur
AU - Kaidar-Person, Orit
AU - Perrucci, Elisabetta
AU - Montero Luis, Angel
AU - Boersma, Liesbeth
AU - Coles, Charlotte
AU - Offersen, Birgitte
AU - Meattini, Icro
AU - Bolukbasi, Yasemin
AU - Leonardi, Maria Cristina
AU - Pfeffer, Raphael
AU - Cutuli, Bruno
AU - Vidali, Cristiana
AU - Franco, Pierfrancesco
AU - Kouloulias, Vassilis
AU - Masiello, Valeria
AU - Rivera, Sofia
AU - Bourgier, Celine
AU - Ciabattoni, Antonella
AU - Lancellotta, Valentina
AU - Trigo, Lurdes
AU - Valentini, Vincenzo
AU - Poortmans, Philip
AU - Aristei, Cynthia
N1 - Funding Information:
The authors declare that they have no conflict of interest. Doctor Charlotte Coles is supported by the National Institute of Health Research (NIHR) Research Professorship and Cambridge Biomedical Research Centre . Dr Ugur Selek is an Accuray Advisory Board.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7
Y1 - 2020/7
N2 - We report on the second Assisi Think Tank Meeting (ATTM) on breast cancer which was held under the auspices of the European Society for RadioTherapy & Oncology (ESTRO). In discussing in-depth current evidence and practice it was designed to identify grey areas in diverse forms of the disease. It aimed at addressing uncertainties and proposing future trials to improve patient care.Before the meeting, three key topics were selected: 1) primary systemic therapy, mastectomy, breast reconstruction and post-mastectomy radiation therapy, 2) therapeutic options in ductal carcinoma in situ, and 3) therapy de-escalation in early stage breast cancer. Clinical practice in these areas was investigated by means of an online questionnaire. The time lapse period between the survey and the meeting was used to review the literature and on-going clinical trials. At the ATTM both were discussed in depth and research protocols were proposed.
AB - We report on the second Assisi Think Tank Meeting (ATTM) on breast cancer which was held under the auspices of the European Society for RadioTherapy & Oncology (ESTRO). In discussing in-depth current evidence and practice it was designed to identify grey areas in diverse forms of the disease. It aimed at addressing uncertainties and proposing future trials to improve patient care.Before the meeting, three key topics were selected: 1) primary systemic therapy, mastectomy, breast reconstruction and post-mastectomy radiation therapy, 2) therapeutic options in ductal carcinoma in situ, and 3) therapy de-escalation in early stage breast cancer. Clinical practice in these areas was investigated by means of an online questionnaire. The time lapse period between the survey and the meeting was used to review the literature and on-going clinical trials. At the ATTM both were discussed in depth and research protocols were proposed.
KW - Breast cancer
KW - Radiation therapy
KW - Neoadjuvant chemotherapy
KW - Breast reconstruction
KW - Post-mastectomy radiation therapy
KW - Ductal carcinoma in situ
KW - De-escalating therapy
KW - Hypofractionation
KW - Partial breast irradiation
KW - CARCINOMA IN-SITU
KW - POSTMASTECTOMY RADIATION-THERAPY
KW - INTENSITY-MODULATED RADIOTHERAPY
KW - PATHOLOGICAL COMPLETE RESPONSE
KW - LUMPECTOMY PLUS TAMOXIFEN
KW - LOCAL-REGIONAL RECURRENCE
KW - SURGICAL ADJUVANT BREAST
KW - LONG-TERM OUTCOMES
KW - 20-YEAR FOLLOW-UP
KW - NEOADJUVANT CHEMOTHERAPY
U2 - 10.1016/j.critrevonc.2020.102967
DO - 10.1016/j.critrevonc.2020.102967
M3 - (Systematic) Review article
C2 - 32450277
SN - 1040-8428
VL - 151
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 102967
ER -